Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

Ordu C., Pilanci K. N. , Avci N., YILDIZ İ., Alco G., Demirhan O., ...More

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.20, no.2, pp.147-152, 2016 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.5114/wo.2016.60069
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.147-152
  • Keywords: metastatic renal cell carcinoma, prognostic factors, dosing schedule, sunitinib toxicity, PHASE-II TRIAL, INTERFERON-ALPHA, CLINICAL-TRIALS, CARCINOMA, HYPOTHYROIDISM, SURVIVAL, HYPERTENSION, INHIBITOR, THERAPIES, BIOMARKER
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Aim of the study: Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug.